BioCentury | Feb 20, 2021
Management Tracks

Biden nominates Brooks-LaSure to lead CMS; plus moves at Everest, Abbisko, NovalGen, Acorda, SVB Capital and Avoro Ventures

...officer. Guo previously served as VP and deputy global brand lead for Lenvima lenvatinib at Eisai...
...in the biopharma practice at New Enterprise Associates. BC Staff Everest Medicines Ltd. Abbisko Therapeutics Co. Ltd. Acorda Therapeutics Inc. Eisai...
BioCentury | Feb 20, 2021
Product Development

Snapshot of Phase III therapies for Alzheimer’s disease: Data Byte

...its June 7 PDUFA date. That leaves lecanemab from Eisai...
BioCentury | Feb 10, 2021
Product Development

First-line RCC immunotherapy combinations shine at ASCO GU

...pembrolizumb plus VEGFR inhibitor Lenvima lenvatinib from Eisai...
...Kisplyx, lenvatinib mesylate (E7080, MK-7902) Merck & Co. Inc. Eisai...
BioCentury | Feb 4, 2021
Deals

Feb. 3 Quick Takes: Hillhouse takes stakes in InnoCare, Luye; plus Merck KGaA, Inivata, Reverie, Neurocrine, Eisai and more

...the Eisai Innovation Center BioLab, an incubator for companies focused on neurological diseases, within the Eisai...
...and regulatory milestones, plus royalties. BC Staff Tepmetko (tepotinib, MSC2156119J) Luye Life Sciences Hillhouse Capital Merck KGaA Inivata Reverie Labs Voyager Therapeutics Neurocrine Biosciences Inc. Eisai Genentech X-Chem InnoCare...
BioCentury | Jan 30, 2021
Distillery Therapeutics

SLC12A5, Rho kinase as targets for mutation-associated intellectual disability

...precursors along the RMS and increased the number of cells reaching the olfactory bulb.Asahi Kasei Corp. (Tokyo:3407), Eisai...
...Pharma Group market Eril to prevent cerebral vasospasm after subarachnoid hemorrhage surgery. Asahi Kasei and Eisai...
BioCentury | Jan 22, 2021
Management Tracks

Woodman to guide Eisai’s cancer unit; plus Mengyu Lu joins Kirkland & Ellis in Hong Kong, and Splice Bio, Tarsus, Verastem, Fulcrum and more

...of Eisai Co. Ltd. (Tokyo:4523), as chief clinical officer of its oncology business group. Before joining Eisai...
...of central lab solutions for EMEA at the Siemens Healthineers unit of Siemens AG (Xetra:SIE). BC Staff Eisai Tarsus...
BioCentury | Jan 12, 2021
Product Development

Lilly’s amyloid therapy not a big step forward from Biogen’s

...from Alzheon Inc. and lecanemab (BAN2401) from Biogen and Eisai...
BioCentury | Dec 16, 2020
Deals

Third strike for Jyseleca takes therapy out of play in U.S. as focus of Gilead, Galapagos deal shifts to IPF

...recently been approved and is co-marketed with Eisai...
BioCentury | Dec 12, 2020
Regulation

Dec. 11 Quick Takes: FDA reveals clearer path for Entresto NDA; plus cancer group files MFN suit, Sinovac, and Merck approvals in China, aducanumab, Atox, and ImmunoGen

...cancer (NSCLC), melanoma and esophageal squamous cell carcinoma.Aducanumab under review in JapanBiogen Inc. (NASDAQ:BIIB) and Eisai...
...28 evaluable patients, with five (18%) complete responses. BC Staff Aduhelm, aducanumab (BIIB037) Entresto, sacubitril/valsartan (LCZ696) Keytruda, pembrolizumab (MK-3475, lambrolizumab) Biogen Eisai...
BioCentury | Nov 17, 2020
Politics, Policy & Law

Biden appoints former pharma lobbyist Ricchetti as White House counselor

...company. Ricchetti Inc., run by Steve Ricchetti’s brother Jeff Ricchetti, registered as a lobbyist for Eisai...
...previous years. Steve Usdin Eli Lilly and Co. Pfizer Inc. Genomics Institute of the Novartis Research Foundation Blue Cross Blue Shield Eisai...
Items per page:
1 - 10 of 1868
BioCentury | Feb 20, 2021
Management Tracks

Biden nominates Brooks-LaSure to lead CMS; plus moves at Everest, Abbisko, NovalGen, Acorda, SVB Capital and Avoro Ventures

...officer. Guo previously served as VP and deputy global brand lead for Lenvima lenvatinib at Eisai...
...in the biopharma practice at New Enterprise Associates. BC Staff Everest Medicines Ltd. Abbisko Therapeutics Co. Ltd. Acorda Therapeutics Inc. Eisai...
BioCentury | Feb 20, 2021
Product Development

Snapshot of Phase III therapies for Alzheimer’s disease: Data Byte

...its June 7 PDUFA date. That leaves lecanemab from Eisai...
BioCentury | Feb 10, 2021
Product Development

First-line RCC immunotherapy combinations shine at ASCO GU

...pembrolizumb plus VEGFR inhibitor Lenvima lenvatinib from Eisai...
...Kisplyx, lenvatinib mesylate (E7080, MK-7902) Merck & Co. Inc. Eisai...
BioCentury | Feb 4, 2021
Deals

Feb. 3 Quick Takes: Hillhouse takes stakes in InnoCare, Luye; plus Merck KGaA, Inivata, Reverie, Neurocrine, Eisai and more

...the Eisai Innovation Center BioLab, an incubator for companies focused on neurological diseases, within the Eisai...
...and regulatory milestones, plus royalties. BC Staff Tepmetko (tepotinib, MSC2156119J) Luye Life Sciences Hillhouse Capital Merck KGaA Inivata Reverie Labs Voyager Therapeutics Neurocrine Biosciences Inc. Eisai Genentech X-Chem InnoCare...
BioCentury | Jan 30, 2021
Distillery Therapeutics

SLC12A5, Rho kinase as targets for mutation-associated intellectual disability

...precursors along the RMS and increased the number of cells reaching the olfactory bulb.Asahi Kasei Corp. (Tokyo:3407), Eisai...
...Pharma Group market Eril to prevent cerebral vasospasm after subarachnoid hemorrhage surgery. Asahi Kasei and Eisai...
BioCentury | Jan 22, 2021
Management Tracks

Woodman to guide Eisai’s cancer unit; plus Mengyu Lu joins Kirkland & Ellis in Hong Kong, and Splice Bio, Tarsus, Verastem, Fulcrum and more

...of Eisai Co. Ltd. (Tokyo:4523), as chief clinical officer of its oncology business group. Before joining Eisai...
...of central lab solutions for EMEA at the Siemens Healthineers unit of Siemens AG (Xetra:SIE). BC Staff Eisai Tarsus...
BioCentury | Jan 12, 2021
Product Development

Lilly’s amyloid therapy not a big step forward from Biogen’s

...from Alzheon Inc. and lecanemab (BAN2401) from Biogen and Eisai...
BioCentury | Dec 16, 2020
Deals

Third strike for Jyseleca takes therapy out of play in U.S. as focus of Gilead, Galapagos deal shifts to IPF

...recently been approved and is co-marketed with Eisai...
BioCentury | Dec 12, 2020
Regulation

Dec. 11 Quick Takes: FDA reveals clearer path for Entresto NDA; plus cancer group files MFN suit, Sinovac, and Merck approvals in China, aducanumab, Atox, and ImmunoGen

...cancer (NSCLC), melanoma and esophageal squamous cell carcinoma.Aducanumab under review in JapanBiogen Inc. (NASDAQ:BIIB) and Eisai...
...28 evaluable patients, with five (18%) complete responses. BC Staff Aduhelm, aducanumab (BIIB037) Entresto, sacubitril/valsartan (LCZ696) Keytruda, pembrolizumab (MK-3475, lambrolizumab) Biogen Eisai...
BioCentury | Nov 17, 2020
Politics, Policy & Law

Biden appoints former pharma lobbyist Ricchetti as White House counselor

...company. Ricchetti Inc., run by Steve Ricchetti’s brother Jeff Ricchetti, registered as a lobbyist for Eisai...
...previous years. Steve Usdin Eli Lilly and Co. Pfizer Inc. Genomics Institute of the Novartis Research Foundation Blue Cross Blue Shield Eisai...
Items per page:
1 - 10 of 1868